Racura Oncology Reaches Significant Milestone in Cardioprotection and Anticancer Trial
Racura Oncology has announced a pivotal moment in the clinical development of its promising drug candidate, RC220. The final patient in the first cohort of the Phase I trial, investigating the cardioprotection and anticancer synergy (CPACS) of RC220 in patients with advanced solid tumours, has successfully received their dosage.
This crucial step was undertaken at Queen Mary Hospital in Hong Kong, where the principal investigator, Dr. Roland Ching-Yu Leung, and his dedicated team administered RC220 to the patient. The treatment, involving a dosage of 40mg/m², proceeded without any reported adverse events, including phlebitis, a common concern with intravenous treatments. This positive outcome follows the successful dosing of the first two patients in the trial, who were treated at the Southside Cancer Care Centre in New South Wales last year.
The completion of recruitment for this initial cohort is a significant achievement, allowing the trial to progress to the next phase. To date, no dose-limiting toxicities have been observed across any of the treated patients, underscoring the potential safety profile of RC220.
Next Steps: Safety Review and Dose Escalation
In accordance with the trial protocol, a comprehensive review of all accumulated safety data from the three patients in the first cohort is now underway. This review will be conducted by the Safety Review Committee (SRC).
Should the SRC provide clearance following their assessment, the trial is set to advance to the next planned RC220 dosage level of 80 mg/m². This escalation is based on the updated trial protocol, which was announced in February.
Understanding the CPACS Phase I Trial
Racura Oncology’s Phase I clinical trial for advanced solid tumours is an open-label study, currently being conducted across multiple esteemed medical facilities in Australia, Hong Kong, and South Korea. The primary objective of the initial stage of this trial is to meticulously assess the safety and tolerability of RC220. This involves administering ascending doses of RC220 in combination with doxorubicin, a widely used chemotherapy drug. The trial aims to enrol up to 33 patients to determine the maximum tolerated combined dose (MTCD).
The Challenge of Doxorubicin: Anthracyclines, such as doxorubicin, are potent chemotherapy agents vital in fighting various cancers. However, a significant drawback of these drugs is their potential to cause long-term, and sometimes debilitating, cardiac damage in a subset of patients.
RC220: A Dual-Action Approach: Racura’s RC220 is a novel, proprietary intravenous formulation of bisantrene. Its innovative design targets cancer cells while simultaneously aiming to shield the heart from the cardiotoxic effects commonly associated with chemotherapy.
Biomarker Analysis: Beyond safety, the first stage will also meticulously examine the effects of RC220 on a range of clinical biomarkers. A key focus will be on a blood-based measure designed to quantify the cardioprotective mechanism of action of RC220.
Stage Two: Expanding the Assessment
Following an interim analysis of the data gathered during the first stage, the trial will transition to its second stage. This phase will involve an additional 20 patients and will focus on evaluating the optimal dosage of RC220 when used in conjunction with doxorubicin.
The primary goals of stage two are to further assess the safety and tolerability of the determined dosage, as well as to gather preliminary signals regarding the cardioprotective and anticancer efficacy of RC220.
Racura has highlighted that the Phase I trial is employing a Bayesian design. This statistical approach is intended to enhance trial flexibility and expedite the process of data analysis and decision-making. Given the open-label nature of the study, patient outcomes are expected to be available relatively soon after treatment. The company intends to provide regular progress updates, although these will not be on an individual patient basis.
A CEO’s Perspective
Dr. Daniel Tillett, CEO of Racura Oncology, expressed his enthusiasm for this significant milestone. “The safe dosing of the third patient in our RC220 solid tumour trial in Hong Kong and the recruitment of the first dose escalation cohort is an important milestone for Racura Oncology,” he stated. “We are grateful to all the patients, investigators, and clinical teams who have made this trial possible, and we look forward to treating patients on the updated protocol.”
